Target intelligence / Profile preview

Indigenous gut microbiota

Molecular classification
Other
01

Overview

"Indigenous gut microbiota" refers to the complex, natural community of microorganisms—including bacteria, archaea, fungi, and viruses—that reside in the human digestive tract. These organisms play integral roles in fermenting unused dietary substrates, producing essential vitamins, modulating the host's immune system, regulating gut and metabolic development, and inhibiting the growth of harmful pathogens[1][3][4][5]. The composition and function of the indigenous gut microbiota can vary widely between individuals and populations, influenced by genetic, environmental, and dietary factors. Alterations in the indigenous gut microbiota (dysbiosis) are associated with numerous diseases, including metabolic, gastrointestinal, and inflammatory conditions[1][4][3]. The indigenous gut microbiota is not a single molecule, protein, or receptor and, therefore, is not a canonical therapeutic target in the strict sense applied to defined receptors or enzymes, but rather a broad ecological target or context for interventions such as probiotics, prebiotics, and FMT[2][4][6]. It is not a receptor, enzyme, or single molecular entity.

Other names
Indigenous gut floraNative gut microbiomeResident gut microbiotaCommensal gut microbiota
02

Mechanism of action

Restoration of microbial diversity (e.g., FMT, probiotics); Modulation of immune response; Inhibition of specific pathogens; Production or consumption of metabolites (e.g., short-chain fatty acids); Competitive exclusion of pathogens; Production of therapeutic proteins (engineered strains)

03

Biological functions

Fermentation of dietary substratesProduction of vitamins (biotin, vitamin K)Modulation of immune systemInhibition of pathogen colonizationRegulation of host metabolismModulation of gut development
04

Disease associations

ObesityInflammatory bowel diseaseIrritable bowel syndromeColorectal cancerCeliac diseaseInfection (pathobiont expansion)Malnutrition
05

Safety considerations

Risk of introducing or expanding pathobionts (potential pathogens)Transmission of antibiotic resistance genesUnpredictable immune responses (especially in immunocompromised hosts)Bacteremia or sepsis following FMT or live biotherapeutics
06

Interacting drugs

Probiotics (e.g., Lactobacillus spp., Bifidobacterium spp.)

5 more in the full profile.

07

Biomarkers

Microbial diversity indices (alpha/beta diversity)Relative abundance of key taxa (e.g., Bacteroides, Faecalibacterium)Metabolite levels (e.g., acetate, propionate, butyrate)Dysbiosis signatures in 16S/shotgun metagenomics

Beyond the preview

Go deeper on Indigenous gut microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indigenous gut microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call